New study aims to unlock secrets of prostate cancer treatment resistance
NCT ID NCT07154914
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study will follow 396 men with metastatic hormone-sensitive prostate cancer to understand how the disease changes over time and becomes resistant to therapy. Participants receive standard treatments like abiraterone plus hormone therapy, and researchers will analyze genetic differences to see which combinations work best. The goal is to improve personalized treatment for advanced prostate cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Abiraterone plus androgen deprivation therapy (ADT)
- What this could lead to
- If successful, this study could help doctors choose the most effective treatment combinations for men with advanced prostate cancer based on their genetic profile.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly test new therapies. Results may not apply to all patients or lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.